And it requires the PDL-1 expression which could really narrow down the numbers. The more we pick it apart the more I am thinking there will be few who qualify.
Correct me if I’m wrong (Please be patient with me. English is not my native language so I’m aware I could miss some nuances) but the PD L-1 status only has to be established . Wether it’s positive, negative or intermediate doesn’t exclude anyone from the trial.
No it is not your English, but my brain not engaging! Yes, it is any PDL expression result. I misread and wondered about that as it wouldn’t tell us much if we only had the PDL positive folks in the trial. Thanks for catching my mistake.
Can you please explain me what is “PDL positive”? Are there any tests like for BRAF mutation which can evaluate if you are “PDL positive” and can react for PDL-therapy (Nivo?)? That means doctors already can predict if you will have positive results with immunomedicine?
That is clear that PD1 has better stats and less side effects, but it is good to see them scientifically tested in trial. I would like to see the two PD1 agents against each other since that isn’t as clear.